Holen Sie sich die Stockscreener-App
27.07
2.16%
-0.636
Schlusskurs vom Vortag:
$27.71
Offen:
$27.96
24-Stunden-Volumen:
91,217
Relative Volume:
0.52
Marktkapitalisierung:
$427.76M
Einnahmen:
$925.00K
Nettoeinkommen (Verlust:
$-90.35M
KGV:
-5.7471
EPS:
-4.7109
Netto-Cashflow:
$-78.52M
1W Leistung:
+0.86%
1M Leistung:
+0.30%
6M Leistung:
+29.16%
1J Leistung:
+56.90%
1-Tages-Spanne:
$27.00
$28.48
1-Wochen-Bereich:
$26.16
$28.48
52-Wochen-Spanne:
$14.65
$37.27
Neurogene Inc Stock (NGNE) Company Profile
Firmenname
Neurogene Inc
Sektor
Branche
Telefon
(877) 237-5020
Adresse
535 W 24TH STREET, NEW YORK
Compare NGNE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
27.07 | 437.87M | 925.00K | -90.35M | -78.52M | -4.7109 |
VRTX
Vertex Pharmaceuticals Inc
|
436.69 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.59 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.19 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.62 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.32 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Craig Hallum | Buy |
| 2025-05-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-21 | Eingeleitet | William Blair | Outperform |
| 2024-01-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-05 | Eingeleitet | Stifel | Buy |
| 2024-01-04 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Neurogene Inc Aktie (NGNE) Neueste Nachrichten
Neurogene’s Stock Run Is Riding A Rett Gene Therapy Bet - Finimize
NGNE News | NEUROGENE INC (NASDAQ:NGNE) - ChartMill
Neurogene Inc. (NGNE) Shows Resilience: Gains 2.45% as Biotech Sector Looks to ReboundCrowd Entry Signals - newser.com
Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear - Bez Kabli
Neurogene (NGNE) Q1 2026 Results Miss Estimates — EPS $-1.39 vs $-1.32Slow Growth Warning - Newser
NGNE Stock Price, Quote & Chart | NEUROGENE INC (NASDAQ:NGNE) - ChartMill
LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceuticals (SPRY) - The Globe and Mail
Neurogene (NGNE) Stock: Down -4.22%, Support Test at $28.45 2026-05-15Turnaround Stocks - Newser
Analysts Are Bullish on Top Healthcare Stocks: Acurx Pharmaceuticals (ACXP), Neurogene (NGNE) - The Globe and Mail
Neurogene (NGNE) Price Target Increased by 11.85% to 60.18 - MSN
Neurogene Inc. Stock 12‑Month Price Target Raised to $77.86, Implies 147% Upside - TradingView
Neurogene 1Q Loss $30.9M >NGNE - Moomoo
Neurogene : Corporate Presentation May 2026 - marketscreener.com
Neurogene: Q1 Earnings Snapshot - marketscreener.com
Neurogene Q1 net loss widens on higher R&D costs - TradingView
Rett gene therapy trial nears full dosing, no HLH cases at 1E15 vg - Stock Titan
Rett gene therapy progress highlights Neurogene (NGNE) Q1 2026 update - Stock Titan
Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Neurogene (NGNE) boosts Rett R&D as Q1 2026 net loss deepens - Stock Titan
Neurogene Inc. unveils new data on ICV gene therapy approach at ASGCT2026 - Traders Union
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy - The Norfolk Daily News
Neurogene Inc. president and CFO sells $300,043 in stock By Investing.com - Investing.com South Africa
Neurogene Inc. president and CFO sells $300,043 in stock - Investing.com India
Neurogene Insider Sold Shares Worth $300,043, According to a Recent SEC Filing - marketscreener.com
Neurogene (NGNE) CFO executes 9,600-share 10b5-1 stock sale - Stock Titan
Neurogene (NGNE) CCO granted 120,000 non-qualified stock options at $28.94 - Stock Titan
Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Cvijic to Sell 14,400 Neurogene Shares (NGNE) via J.P. Morgan - Stock Titan
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
What Neurogene (NGNE) is doing that separates it from the herd (Market Focus) 2026-05-06Weak Sell Signals - Newser
We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business Growth - Yahoo Finance
Jennison Associates LLC Increases Holdings in Neurogene Inc. $NGNE - MarketBeat
Neurogene (NGNE) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
ICV delivery approach for CNS gene therapy set for American Society of Gene and Cell Therapy meeting, Neurogene Inc. - Traders Union
Guggenheim reiterates Neurogene stock rating with $69 target By Investing.com - Investing.com Australia
Guggenheim Initiates Neurogene(NGNE.US) With Buy Rating, Announces Target Price $69 - Moomoo
Why Neurogene chose a brain-delivery route for Rett gene therapy - Stock Titan
Guggenheim reiterates Neurogene stock rating with $69 target - Investing.com
NGNE Neurogene posts narrower Q4 2025 loss than consensus estimates, edges down modestly in today’s trading. - Cổng thông tin điện tử tỉnh Lào Cai
Neurogene (NGNE) Chief Commercial Officer listed in new Form 3 - Stock Titan
Neurogene names commercial chief, adds board member By Investing.com - Investing.com Australia
Neurogene (NGNE) Stock: Is It Showing Downtrend Signals (Bullish Sentiment) 2026-04-20Top Breakouts - Xã Thanh Hà
Neurogene appoints Christy Shafer as CCO - The Pharma Letter
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail to Board of Directors; Advances NGN-401 Gene Therapy for Rett Syndrome - Minichart
Neurogene names commercial chief, adds board member - Investing.com
Neurogene Expands Leadership Team to Drive NGN-401 Commercialization - TipRanks
Neurogene appoints Christy Shafer as chief commercial officer and Christine Mikail, J.D., to board of directors - marketscreener.com
Neurogene Inc. appoints Christy Shafer as Chief Commercial Officer and adds Christine Mikail to board - Traders Union
New CCO and board role strengthen Neurogene (NASDAQ: NGNE) leadership - Stock Titan
Finanzdaten der Neurogene Inc-Aktie (NGNE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):